The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Open accessAbstract
Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises. Here, CD33 and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients with detailed information on French-American-British/World Health Organization (FAB/WHO) classification, cytogenetics and molecular aberrations. AMLs of 87.8% express CD33 and would therefore be targetable with anti-CD33 therapies. Additionally, 9.4% of AMLs express CD123 without concomitant CD33 expression. Thus, nearly all AMLs could be either targeted via CD33 or CD123. Simultaneous presence of both antigens was observed in 69.5% of patients. Most importantly, even AMLs with adverse cytogenetics express CD33 and CD123 levels comparable to those with favorable and intermediate subtypes. Some patient groups with unfavorable alterations, such as FMS-related tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations, high FLT3-ITD mutant/wild-type ratios and monosomy 5 are even characterized by high expression of CD33 and CD123. In addition, blasts of patients with mutant nucleophosmin (NPM1) revealed significantly higher CD33 and CD123 expression pointing toward the possibility of minimal residual disease-guided interventions in mutated NPM1-positive AMLs. These results stimulate the development of novel concepts to redirect immune effector cells toward CD33- and CD123-expressing blasts using bi-specific antibodies or engineered T cells expressing chimeric antigen receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationThe origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
Stem cell gene expression programs influence clinical outcome in human leukemia
Eppert, K., Takenaka, K., Lechman, E. R., Waldron, L., Nilsson, B., van Galen, P., Metzeler, K. H., Poeppl, A., Ling, V., Beyene, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2415 · Cited by 1,041
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Thiede, C., Koch, S., Creutzig, E., Steudel, C., Illmer, T., Schaich, M., Ehninger, G., & (DSIL), F. T. D. S. L. (2006) · Blood · doi:10.1182/blood-2005-08-3167 · Cited by 736
Self-citationCoexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
Goardon, N., Marchi, E., Atzberger, A., Quek, L., Schuh, A., Soneji, S., Woll, P., Mead, A., Alford, K. A., Rout, R., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.012 · Cited by 653
Jin, L., Lee, E. M., Ramshaw, H. S., Busfield, S. J., Peoppl, A. G., Wilkinson, L., Guthridge, M. A., Thomas, D., Barry, E. F., Boyd, A., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.04.018 · Cited by 522
Gilliet, M., Conrad, C., Geiges, M., Cozzio, A., Thürlimann, W., Burg, G., Nestle, F. O., & Dummer, R. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.12.1490 · Cited by 408
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells
Griffin, J. D., Linch, D., Sabbath, K., Larcom, P., & Schlossman, S. F. (1984) · Leukemia Research · doi:10.1016/0145-2126(84)90001-8 · Cited by 403
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-10-118331 · Cited by 373
Taussig, D. C., Vargaftig, J., Miraki-Moud, F., Griessinger, E., Sharrock, K., Luke, T., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2010) · Blood · doi:10.1182/blood-2009-02-206565 · Cited by 366
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies.
Muñoz, L., Nomdedeu, J. F., López, O., Carnicer, M. J., Bellido, M., Aventin, A. M., Brunet, S., & Sierra, J. (2001) · PubMed · Cited by 269
Röllig, C., Bornhäuser, M., Thiede, C., Taube, F., Kramer, M., Mohr, B., Aulitzky, W., Bodenstein, H., Tischler, H.-J., Stuhlmann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8500 · Cited by 265
Self-citationHepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy
Rajvanshi, P., Shulman, H. M., Sievers, E. L., & McDonald, G. B. (2002) · Blood · doi:10.1182/blood.v99.7.2310 · Cited by 246
Expression of normal myeloid-associated antigens by acute leukemia cells
Dinndorf, P., Andrews, R., Benjamin, D., Ridgway, D., Wolff, L., & Bernstein, I. (1986) · Blood · doi:10.1182/blood.v67.4.1048.1048 · Cited by 229
Lo-Coco, F. (2004) · Blood · doi:10.1182/blood-2004-04-1550 · Cited by 225
Shayegi, N., Kramer, M., Bornhäuser, M., Schaich, M., Schetelig, J., Platzbecker, U., Röllig, C., Heiderich, C., Landt, O., Ehninger, G., et al. (2013) · Blood · doi:10.1182/blood-2012-10-461749 · Cited by 196
Self-citationWalter, R. B., Gooley, T. A., van der Velden, V. H. J., Loken, M. R., van Dongen, J. J. M., Flowers, D. A., Bernstein, I. D., & Appelbaum, F. R. (2007) · Blood · doi:10.1182/blood-2006-09-047399 · Cited by 195
Burnett, A. K., Hills, R. K., Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., Yin, J., McMullin, M. F., Dignum, H., Bowen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2012.229 · Cited by 161
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells
Hauswirth, A. W., Florian, S., Printz, D., Sotlar, K., Krauth, M. ‐., Fritsch, G., Schernthaner, G. ‐., Wacheck, V., Selzer, E., Sperr, W. R., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01746.x · Cited by 158
Current and emerging therapies for acute myeloid leukemia
Robak, T., & Wierzbowska, A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.017 · Cited by 154
Florian, S., Sonneck, K., Hauswirth, A. W., Krauth, M., Schernthaner, G.-H., Sperr, W. R., & Valent, P. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500272507 · Cited by 151
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
Kügler, M., Stein, C., Kellner, C., Mentz, K., Saul, D., Schwenkert, M., Schubert, I. A., Singer, H., Oduncu, F. S., Stockmeyer, B., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08300.x · Cited by 137
Aigner, M., Feulner, J., Schaffer, S., Kischel, R., Kufer, P., Schneider, K., Henn, A., Rattel, B., Friedrich, M., Baeuerle, P. A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.341 · Cited by 130
Andrews, R., Takahashi, M., Segal, G. M., Powell, J., Bernstein, I. D., & Singer, J. W. (1986) · Blood · doi:10.1182/blood.v68.5.1030.1030 · Cited by 118
Propris, M. S. D., Raponi, S., Diverio, D., Milani, M. L., Meloni, G., Falini, B., Foà, R., & Guarini, A. R. (2011) · Haematologica · doi:10.3324/haematol.2011.043786 · Cited by 106
Robertson, M. J., Soiffer, R. J., Freedman, A. S., Rabinowe, S. N., Anderson, K. C., Ervin, T., Murray, C., Dear, K. B. G., Griffin, J. D., & Nadler, L. M. (1992) · Blood · doi:10.1182/blood.v79.9.2229.2229 · Cited by 98
Stein, C., Kellner, C., Kügler, M., Reiff, N., Mentz, K., Schwenkert, M., Stockmeyer, B., Mackensen, A., & Fey, G. H. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08033.x · Cited by 71
Arndt, C., Bonin, M. V., Cartellieri, M., Feldmann, A., Koristka, S., Michalk, I., Stamova, S., Bornhäuser, M., Schmitz, M., Ehninger, G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.18 · Cited by 71
Self-citationArndt, C., Feldmann, A., Bonin, M. V., Cartellieri, M., Ewen, E.-M., Koristka, S., Michalk, I., Stamova, S., Berndt, N., Gocht, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.243 · Cited by 64
Self-citationHwang, K., Park, C., Jang, S., Chi, H., Kim, D., Lee, J., Lee, J., Lee, K. H., Im, H., & Seo, J. J. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1501-7 · Cited by 58
CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues
Hoyer, J. D., Grogg, K. L., Hanson, C. A., Gamez, J. D., & Doǧan, A. (2008) · American Journal of Clinical Pathology · doi:10.1309/e36008y2h08q1ayy · Cited by 54
Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
ten Cate, B., de Bruyn, M., Wei, Y., Bremer, E., Helfrich, W., Mourabet, M. E., El‐Hachem, S., Harrison, J., & Binion, D. G. (2009) · Current Drug Targets · doi:10.2174/138945010790031063 · Cited by 45
Riccioni, R., Diverio, D., Riti, V., Buffolino, S., Mariani, G., Boe, A., Cedrone, M., Ottone, T., Foà, R., & Testa, U. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07491.x · Cited by 45
Rollins‐Raval, M. A., Pillai, R. K., Warita, K., Warita, T., Mehta, R. S., Boyiadzis, M. M., Djokic, M., Kant, J. A., & Roth, C. G. (2012) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318261a342 · Cited by 44
Oelschlaegel, U., Mohr, B., Schaich, M. A., Schäkel, U., Kroschinsky, F., Illmer, T., Ehninger, G., & Thiede, C. (2009) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20475 · Cited by 42
Self-citationFavaloro, E. J., Bradstock, K. F., Kabral, A., Grimsley, P. G., Zowtyj, H. N., & Zola, H. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb07618.x · Cited by 41
Mohr, B., Schetelig, J., Schäfer‐Eckart, K., Schmitz, N., Hänel, M., Rösler, W., Frickhofen, N., Link, H., Neubauer, A., Schuler, U. S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12253 · Cited by 28
Self-citationKhoury, H., Dalal, B. I., Nantel, S. H., Horsman, D. E., Lavoie, J. C., Shepherd, J. D., Hogge, D. E., Toze, C. L., Song, K., Forrest, D. L., et al. (2004) · Modern Pathology · doi:10.1038/modpathol.3800168 · Cited by 23
Dual-Targeting for the Elimination of Cancer Cells with Increased Selectivity
Schubert, I. A., Stein, C., & Fey, G. H. (2012) · Antibodies · doi:10.3390/antib1010002 · Cited by 17
Cited by
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Metadata
- Authors
- Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., Oelschlägel, U., & on behalf of the Study Alliance Leukemia
- Venue
- Blood Cancer Journal
- Published
- 2014-06-13
- Volume
- 4
- Issue
- 6
- Pages
- e218-e218
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W2008748351
- Cited by
- 355
- References
- 53
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.